Small-Cap Investor Forum

[MissionIR]

Recap of Stellar Biotechnologies Inc. (SBOTF) and its Accomplishments This Past Year

Since becoming a leader of Keyhole Limpet Hemocyanin (KLH) production, Stellar Biotechnologies Inc. (OTCQB: SBOTF) continues its objectives towards commercial expansion of its product with immunotherapy treatments. KLH is an immune stimulating protein that aids in fighting immune deficient illnesses like cancer, Alzheimer’s Disease, and many inflammatory diseases. The company has successfully maintained its partnerships with various companies to meet its goals.

Since 2013, Stellar and Amaran Biotechnologies Inc. have collaborated on manufacturing the OBI-822 immunotherapy that uses KLH as an important immune stimulator. The companies have completed all of their initial objectives and will now focus on commercial manufacturing to the wider market. Similarly, in April 2015, Stellar expanded its agreement with Neovacs S.A. to continue supplying the company with Stellar KLH in their IFNa-Kinoid immunotherapy treatment of Lupus.

To keep up with emerging immunotherapy innovations, Stellar collaborated with Ostiones Guerrero SA de CV in July to obtain a site in Baja California, Mexico to develop another aquaculture production location. The company expects to use this location in hopes of accelerating KLH production to meet the needs of the growing market.

With the goal of expansion, Stellar recently consolidated the company’s common shares (outstanding and issued) on the grounds of one (1) post-consolidated share for every ten (10) pre-consolidated shares in a reverse stock split maneuver so that these shares can be traded on the NASDAQ market. With NASDAQ’s approval, this could help Stellar spread its brand to more investors while increasing assets to shareholders.

Stellar still commits to new technology related to KLH and how to use its different forms effectively in various treatments. To solidify its unswerving goals, the company presented a poster at the Annual Meeting of the American Association of Immunologists called, “Measuring the Properties of Different Forms of Keyhole Limpet Hemocyanin (KLH) Reveals Important Differences.” This highlights the different ways KLH can prompt immune responses in various therapies.

The company also stands behind the United Nations’ September declaration of protecting and using oceans for sustainable development. This declaration aligns with Stellar’s mission of using aquaculture science to manufacture more KLH for therapies.

In May, the company expanded its online communication to Facebook, Twitter, and Google+/YouTube to convey educational content and updates. By spreading its brand, Stellar aims to collaborate with more immunotherapy manufacturers to bring successful treatments to patients while also creating valuable stock to investors.

For more information on Stellar Biotechnolgies Inc., please visit http://www.stellarbiotechnologies.com